Daily non-political popular news in brief.
Fresh use of targeted therapy advances treatment of early HER2-positive breast cancer
11-16-2006 · EurekAlert!The news that the world's first targeted therapy, trastuzumab (Herceptin), is now available for many women with early-stage HER2-positive breast cancer "highlights a truly significant advance in the management of breast cancer," says Edith Perez, M.D., director of Mayo Clinic's Breast Clinic in Jacksonville, Florida.
Read more »
Keywords: fresh, targeted, therapy, advances, treatment, her2-positive, breast, cancer, advance, her2, positive
« Previous | Next »
Similar news on "Fresh use of targeted therapy advances treatment of early HER2-positive breast cancer":
- Gene profiling predicts resistance to breast cancer drug Herceptin
02-20-2007 · EurekAlert!
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.
Similar news · Read more »
- Drug combination shrinks breast cancer metastases in brain
12-16-2007 · EurekAlert!
A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.
Similar news · Read more »
- Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
12-14-2007 · EurekAlert!
The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth. Prior to this report, there were conflicting opinions about whether that was the case, say Mayo Clinic investigators who presented their findings at the San Antonio Breast Cancer Symposium.
Similar news · Read more »
- Mass. General leading international trial of novel breast cancer drug
12-13-2006 · EurekAlert!
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor.
Similar news · Read more »
- Epigenetic drugs, promising for breast cancer treatment
12-20-2006 · EurekAlert!
Worldwide, cancer persists as one of the most important diseases that affect the human being. The knowledge on the molecular bases of cancer generated during the last decades has been successfully translated into small but significant gains in overall cancer survival rates due to better primary prevention measures, improved diagnostic methods and the development of more effective and specific therapies, collectively termed "molecular targeted therapies." In the context of these new forms of treatment, epigenetic or transcriptional cancer therapy is clearly promising.
Similar news · Read more »
- Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators
02-15-2008 · EurekAlert!
How did a failed contraceptive become the first targeted therapy for the treatment of breast cancer? The transformation of tamoxifen, from cast-off to lifesaver, laid the foundation for a new class of therapeutics -- selective estrogen receptor modulators. V. Craig Jordan, a researcher at the Fox Chase Cancer Center in Philadelphia, Jordan reports on efforts to use the lessons from tamoxifen to develop new hormone receptor-related drugs for both women and men.
Similar news · Read more »
- Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
- Anthracyclines improve survival in HER2-positive breast cancer patients
12-25-2007 · EurekAlert!
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.
Similar news · Read more »
- High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
12-13-2007 · EurekAlert!
High-dose chemotherapy and autologous stem cell transplantation, the controversial, arduous, yet once-popular combination treatment that fell out of favor as a therapy for breast cancer, has proven not to be beneficial as an adjuvant therapy for women with node-positive disease, according to an expansive analysis conducted by researchers at the University of Texas M. D. Anderson Cancer Center.
Similar news · Read more »
- 1 in 5 early-stage breast cancer patients may not follow hormonal therapy plan
12-16-2006 · EurekAlert!
Postmenopausal women with early-stage, hormone-sensitive breast cancer have a lower risk of disease recurrence when their treatment includes a new class of hormone therapy drugs, yet one out five women prescribed the drugs may not take them regularly.
Similar news · Read more »
